Attached files

file filename
EX-99.1 - EXHIBIT 99.1 EARNINGS RELEASE - SYNLOGIC, INC.mirna-2017q1earningsrelease.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2017
 
 
Mirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
 
 
Delaware
     
001-37566
     
26-1824804
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification Number)
 
1250 South Capital of Texas Highway
Austin, TX 78746


(Address of principal executive offices, including Zip Code)
 
Registrant’s telephone number, including area code: (512) 901-0950
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
















Item 2.02   Results of Operations and Financial Condition.
 
On May 9, 2017, Mirna Therapeutics, Inc. (“Mirna”) issued a press release announcing its financial results for the three months ended March 31, 2017. The press release is attached hereto as Exhibit 99.1.
 
The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing of Mirna under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
Item 9.01 Financial Statements and Exhibits.
 
(d)  Exhibits.
 
 
 
 
Exhibit
No.
    
Description
99.1
 
Press release dated May 9, 2017.






SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
MIRNA THERAPEUTICS, INC.
 
 
Date: May 9, 2017

By:
/s/ Alan Fuhrman
 
 
Alan Fuhrman
 
 
Chief Financial Officer